Tags

Type your tag names separated by a space and hit enter

Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population.
J Rheumatol 2012; 39(12):2303-9JR

Abstract

OBJECTIVE

Systemic sclerosis (SSc) is a chronic autoimmune disease. The objective of our study was to estimate the medical costs and healthcare resource use of subjects with SSc in a large US managed care plan.

METHODS

Subjects at least 18 years of age and with claims-based evidence of SSc (ICD-9-CM code 710.1x) were identified from a health plan database from 2003 through 2008. Subjects were matched to unaffected controls, based on index date, age, sex, geographic region, time on insurance, and comorbidity score. Costs and resource use were identified during the 12-month postindex period. A generalized linear model (GLM) was used to estimate costs, controlling for demographic and clinical characteristics.

RESULTS

In this study, 1648 subjects with SSc were matched to 4944 controls. Mean overall annual medical costs were higher among SSc subjects than controls ($17,365 vs $5,508; p < 0.001). A GLM model supported these results. Evidence of lung disease, gastrointestinal bleeding, or renal disease increased costs (all p < 0.001). Compared to controls, significantly higher proportions of SSc subjects had postindex ambulatory visits, emergency department visits, and inpatient hospital stays (all p < 0.001).

CONCLUSION

Our findings suggest that the medical costs and resource use associated with treating SSc are high (compared to matched controls), and as expected, subjects with serious disease complications experience the highest costs.

Authors+Show Affiliations

University of California, Los Angeles, Los Angeles, CA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23027885

Citation

Furst, Daniel E., et al. "Annual Medical Costs and Healthcare Resource Use in Patients With Systemic Sclerosis in an Insured Population." The Journal of Rheumatology, vol. 39, no. 12, 2012, pp. 2303-9.
Furst DE, Fernandes AW, Iorga SR, et al. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. J Rheumatol. 2012;39(12):2303-9.
Furst, D. E., Fernandes, A. W., Iorga, S. R., Greth, W., & Bancroft, T. (2012). Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. The Journal of Rheumatology, 39(12), pp. 2303-9. doi:10.3899/jrheum.120600.
Furst DE, et al. Annual Medical Costs and Healthcare Resource Use in Patients With Systemic Sclerosis in an Insured Population. J Rheumatol. 2012;39(12):2303-9. PubMed PMID: 23027885.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. AU - Furst,Daniel E, AU - Fernandes,Ancilla W, AU - Iorga,Serban R, AU - Greth,Warren, AU - Bancroft,Tim, Y1 - 2012/10/01/ PY - 2012/10/3/entrez PY - 2012/10/3/pubmed PY - 2013/5/15/medline SP - 2303 EP - 9 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 39 IS - 12 N2 - OBJECTIVE: Systemic sclerosis (SSc) is a chronic autoimmune disease. The objective of our study was to estimate the medical costs and healthcare resource use of subjects with SSc in a large US managed care plan. METHODS: Subjects at least 18 years of age and with claims-based evidence of SSc (ICD-9-CM code 710.1x) were identified from a health plan database from 2003 through 2008. Subjects were matched to unaffected controls, based on index date, age, sex, geographic region, time on insurance, and comorbidity score. Costs and resource use were identified during the 12-month postindex period. A generalized linear model (GLM) was used to estimate costs, controlling for demographic and clinical characteristics. RESULTS: In this study, 1648 subjects with SSc were matched to 4944 controls. Mean overall annual medical costs were higher among SSc subjects than controls ($17,365 vs $5,508; p < 0.001). A GLM model supported these results. Evidence of lung disease, gastrointestinal bleeding, or renal disease increased costs (all p < 0.001). Compared to controls, significantly higher proportions of SSc subjects had postindex ambulatory visits, emergency department visits, and inpatient hospital stays (all p < 0.001). CONCLUSION: Our findings suggest that the medical costs and resource use associated with treating SSc are high (compared to matched controls), and as expected, subjects with serious disease complications experience the highest costs. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/23027885/Annual_medical_costs_and_healthcare_resource_use_in_patients_with_systemic_sclerosis_in_an_insured_population_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&amp;pmid=23027885 DB - PRIME DP - Unbound Medicine ER -